Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Inclusion Criteria Concurrent Treatment: Allowed: Aerosolized pentamidine. Prior Medication: Allowed: Aerosolized pentamidine. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: AIDS as defined by the CDC (except for those with HIV "wasting syndrome"). Significant hepatic disease. Thrombocytopenia (< 75000 platelets/mm3). Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within 30 days prior to entry. Hemophilia A or B or other hematologic disorders requiring current or previous administration of blood products. Known hypersensitivity to thymopentin. Prior Medication: Excluded within 30 days of study entry: Immunomodulatory or experimental therapy. Excluded within 90 days of study entry: Zidovudine (AZT). Patients must not have: AIDS as defined by the CDC (except for those with HIV "wasting syndrome"). Significant hepatic disease. Thrombocytopenia (< 75000 platelets/mm3). Patients with the following conditions are included: Seropositive for HIV-1 (ELISA assay) confirmed by Western blot. HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of patient's peripheral blood monocytes (PBMC) on two separate occasions. HIV "wasting syndrome". Must voluntarily sign consent. History of intravenous drug abuse.